News & Analysis on Clinical Trial Services & Contract Research And Development
The problem of drug tampering and counterfeiting came to the fore again yesterday after it emerged that bottles of GlaxoSmithKline's widely-used HIV drug Combivir (lamivudine and zidovudine) actually contained another HIV drug sold by the drugmaker.
Shares in US biotech ImClone Systems fell on Tuesday after a highly-anticipated trial of its cancer drug Erbitux (cetuximab) in pancreatic cancer failed to live up to expectations.
Clinical trials are saving lives but may be killing the environment due to their 'intensive energy use' and 'substantial contribution to greenhouse gasses.'
A new peptide library could make it easier for drug developers to fully exploit the known therapeutic effects of venoms.
Charles River Laboratories' portable endotoxin testing system, the Endosafe PTS, has been successfully used to detect bacteria on the International Space Station (ISS).
Now is an ideal time for small biotechs to ink that perfect deal with big pharma, attendees heard at the recently held Biotrinity conference in Oxfordshire, UK.
Millipore has added a small-volume unit to the NovaSeptum range of sterile disposable sampling systems it acquired with Swedish company NovAseptic in July 2005.
US firm Vical has announced study results revealing a flu vaccine reinforced with the firm's Vaxfectin adjuvant results in an antibody response 60 times higher than the vaccine alone, and allowed a 10-fold reduction in vaccine dose.
The first commercially available microarray based assay for microRNA (miRNA) has been launched by Agilent to aid in drug discovery research programs.
Pfizer has given an insight into what it is about smaller companies that makes the world's largest pharma company want to buy them.
Major biopharma Gilead Sciences has announced plans to invest in a new €60m plant in west Dublin, Ireland, to expand manufacturing capacity and meet future growth targets.
Amgen is seeing its chief financial officer (CFO) walk away while the Californian biotech giant tries to heal its wounds after a difficult year.